Report: Merck explores $15B drug portfolio sale

Merck (MRK) is considering the potential sale of a portfolio of off-patent drugs which could command more than $15B, Reuters reports.

MRK, which also is in the process of selling its $14B consumer healthcare unit, is said to be working with an investment bank on the potential sale of the portfolio of mature drugs, which could draw interest from generic drugmakers.

The sale process would underscore efforts by large drugmakers to shed smaller divisions they view as non-core so they can better focus on their mainstay products.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs